We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbingdon Healt. Regulatory News (ABDX)

Share Price Information for Abingdon Healt. (ABDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.00
Bid: 9.50
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 1.00 (10.526%)
Open: 10.00
High: 10.00
Low: 10.00
Prev. Close: 10.00
ABDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Salistick™ to be launched in Tesco

15 Aug 2023 07:00

RNS Number : 2745J
Abingdon Health PLC
15 August 2023
 

Abingdon Health plc

("Abingdon Health" or "the Company")

 

Salistick, the first ever saliva pregnancy test, to be launched in Tesco

 

York, U.K. 15 August 2023: Abingdon Health plc (AIM: ABDX), is pleased to announce that Tesco will roll-out Salistick™, the first-ever saliva pregnancy test, in 298 stores and online at Tesco.com from late-August 2023.

 

The launch of Salistick™ will be focused on larger Tesco stores as well as online at Tesco.com. This follows the initial launch of Salistick™ with Superdrug in 400 stores and online at Superdrug.com.

 

The Salistick™ pregnancy test offers women an improved user experience, with high accuracy for early pregnancy detection. The revolutionary patented technology allows saliva to be used as a sample rather than the traditional urine sample. Salistick™ offers the ability to test anywhere, anytime, and for the testing experience to be shared with a partner and other loved ones. It is estimated that 12.5 million pregnancy tests were performed in the UK in 2022. The global pregnancy test kits market was valued at USD 1.70 billion in 2022 and is expected to reach USD 2.28 billion by 2028, growing at a CAGR of 5.08%(1).

 

Abingdon Health is the exclusive distributor of Salistick™ in the UK and Ireland on behalf of Salignostics Limited, an Israeli developer of innovative saliva-based diagnostics tests. As well as providing distribution support Abingdon Health has been providing Salignostics with contract development services to scale-up the Salistick™ product for manufacture and will continue to provide Salignostics with contract manufacturing services going forward.

 

Chris Yates, CEO of Abingdon Health plc, commented: "We are delighted to announce the launch of Salistick with Tesco, online and rolled-out across nearly 300 larger Tesco stores. This novel technology provides women with an enhanced user-experience; offering the ability to test anywhere, anytime, and for the testing experience to be shared with a partner and other loved ones. We continue to explore distribution opportunities for Salistick both in the UK and internationally and we look forward to launching the Salistick dual pack in due course."

 

Sources:

1. Pregnancy Test Kits Market Size, Share, Trends, Growth Forecast (arizton.com)

 

Enquiries

 

Abingdon Health plc

www.abingdonhealth.com/investors/

Chris Yates, Chief Executive Officer

Via Walbrook PR

Melanie Ross, Chief Financial Officer

 

Chris Hand, Non-Executive Chairman

 

 

 

Singer Capital Markets (Sole Broker and Nominated Adviser)

Tel: +44 (0)20 7496 3000

Peter Steel, Alex Bond (Corporate Finance)

 

Tom Salvesen (Corporate Broking)

 

 

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com

Paul McManus / Phillip Marriage

Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

+44 (0)7407 804 654

About Abingdon Health plc

Abingdon Health is a leading lateral flow contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success."

 

The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. 

 

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test ecommerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com

 

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSFEFILEDSEIA
Date   Source Headline
25th Mar 20247:00 amRNSDesign freeze completion & strategic partnership
20th Mar 20247:00 amRNSLaunch of OEM self-tests in Boots
15th Mar 20241:00 pmRNSCEO Interview
14th Mar 20247:00 amRNSInterim Results
11th Mar 20248:53 amRNSNotice of Results
11th Jan 20247:01 amRNSUpdate to Shareholder Concert Parties
11th Jan 20247:00 amRNSTrading Update
15th Dec 202310:15 amRNSResult of AGM
15th Dec 20237:00 amRNSAGM Statement
22nd Nov 20237:00 amRNSNotice of Annual General Meeting
25th Oct 20237:00 amRNSDirector/PDMR Shareholding
24th Oct 20237:01 amRNSAward of Options under LTIP
24th Oct 20237:00 amRNSAppointment of Interim Finance Director
18th Oct 20237:00 amRNSDirectorate Change
17th Oct 20237:00 amRNSFinal Results
11th Oct 20237:00 amRNSNotice of Results
7th Sep 20237:00 amRNSPartnership with Morrama
30th Aug 20237:00 amRNSAgreed changes to Concert Party
15th Aug 20237:00 amRNSSalistick™ to be launched in Tesco
6th Jul 20237:00 amRNSTrading Update
19th Jun 20237:00 amRNSLaunch of Salistick™ saliva pregnancy test
31st Mar 20237:00 amRNSInterim Results
24th Mar 202312:30 pmRNSNotice of Results
20th Mar 20237:00 amRNSSenzo & Abingdon enter into strategic partnership
7th Mar 20237:00 amRNSAppDx® granted further patent
1st Mar 20237:00 amRNSDirector Share Transfer to Trust
28th Feb 20239:05 amRNSSecond Price Monitoring Extn
28th Feb 20239:00 amRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSTrading Update
19th Dec 202210:29 amRNSResult of AGM
19th Dec 20227:01 amRNSAward of Options under new LTIP Scheme
19th Dec 20227:00 amRNSAGM Statement
24th Nov 20229:05 amRNSSecond Price Monitoring Extn
24th Nov 20229:00 amRNSPrice Monitoring Extension
24th Nov 20227:00 amRNSPreliminary Results
23rd Nov 20227:00 amRNSNotice of AGM and Notice of Results
10th Oct 202211:06 amRNSSecond Price Monitoring Extn
10th Oct 202211:00 amRNSPrice Monitoring Extension
10th Oct 20227:00 amRNSFurther re. Outcome of Judicial Review
7th Oct 20225:16 pmRNSFurther re. Outcome of Judicial Review
7th Oct 20224:41 pmRNSSecond Price Monitoring Extn
7th Oct 20224:36 pmRNSPrice Monitoring Extension
7th Oct 20223:29 pmRNSOutcome of Judicial Review
7th Oct 20222:06 pmRNSSecond Price Monitoring Extn
7th Oct 20222:00 pmRNSPrice Monitoring Extension
7th Oct 202210:35 amRNSJudicial Review – judgement expected at 3pm
7th Oct 20227:00 amRNSJudicial Review – judgement expected
26th Sep 20221:26 pmRNSDirector/PDMR Shareholding
16th Sep 20224:19 pmRNSDirector/PDMR Shareholding
15th Aug 20229:06 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.